---
figid: PMC9560885__10555_2022_10066_Fig2_HTML
figtitle: 'Race to develop oral SERDs and other novel estrogen receptor inhibitors:
  recent clinical trial results and impact on treatment options'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
- Danio rerio
pmcid: PMC9560885
filename: 10555_2022_10066_Fig2_HTML.jpg
figlink: /pmc/articles/PMC9560885/figure/Fig2/
number: F2
caption: 'Estrogen receptor signaling pathways: genomic or NISS pathways and the non-genomic
  or MISS pathway. AKT, protein kinase B; CoA, co-activator; CoR, co-activator receptor;
  CDK4/6, cyclin-dependent kinase 4/6; ER, estrogen receptor; ERE, estrogen responsive
  element; FGFR, fibroblast growth factor receptor; HER2, epidermal growth factor
  receptor 2; IGF1, insulin growth factor 1; MISS, membrane-initiated steroid signaling;
  mTORi, mammalian target of rapamycin inhibitors; MAPK, mitogen-activated protein
  kinase; NISS, nuclear-initiated steroid signaling; PI3Ki, phosphoinositide 3-kinase
  inhibitor; TFs, transcription factors'
papertitle: 'The race to develop oral SERDs and other novel estrogen receptor inhibitors:
  recent clinical trial results and impact on treatment options.'
reftext: Yating Wang, et al. Cancer Metastasis Rev. 2022 Oct 14 ;41(4):975-990.
year: '2022'
doi: 10.1007/s10555-022-10066-y
journal_title: Cancer Metastasis Reviews
journal_nlm_ta: Cancer Metastasis Rev
publisher_name: Springer US
keywords: Selective estrogen receptor degraders | Clinical trials | Protein degradation
  | Oral SERDs | PROTC | LYTAC | RIBOTAC | Aptamers
automl_pathway: 0.9467033
figid_alias: PMC9560885__F2
figtype: Figure
redirect_from: /figures/PMC9560885__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9560885__10555_2022_10066_Fig2_HTML.html
  '@type': Dataset
  description: 'Estrogen receptor signaling pathways: genomic or NISS pathways and
    the non-genomic or MISS pathway. AKT, protein kinase B; CoA, co-activator; CoR,
    co-activator receptor; CDK4/6, cyclin-dependent kinase 4/6; ER, estrogen receptor;
    ERE, estrogen responsive element; FGFR, fibroblast growth factor receptor; HER2,
    epidermal growth factor receptor 2; IGF1, insulin growth factor 1; MISS, membrane-initiated
    steroid signaling; mTORi, mammalian target of rapamycin inhibitors; MAPK, mitogen-activated
    protein kinase; NISS, nuclear-initiated steroid signaling; PI3Ki, phosphoinositide
    3-kinase inhibitor; TFs, transcription factors'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Coa
  - Pi3K92E
  - Cor
  - cort
  - cora
  - Crz
  - MKP-4
  - p38b
  - rl
  - Akt
  - InR
  - gfr
  - nac
  - if
  - CycE
  - cyc
  - Cdk4
  - EGFR
  - ERBB2
  - MAPK1IP1L
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - CCND1
  - FCGR1A
  - FCGR1BP
  - FCGR1CP
  - RAPGEF5
  - PSEN2
  - TFF1
  - TAS2R64P
  - CDK6
  - CDK4
  - MMUT
  - ESR1
  - egfra
  - her2
  - igf1
  - napbb
  - ccnd1
  - cdk6
  - cdk4
  - mmut
  - esr1
  - akap12b
---
